Cambridge, Massachusetts-based Verve Therapeutics, a next-generation cardiovascular company, has raised $63 million in Series A2 funding. GV led the round with participation from ARCH Venture Partners, F-Prime Capital, Biomatics Capital, Wellington Management and Casdin Capital.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: